Digest Network Come funziona
Network
/
Società
HA
Non verificato

HAYA Therapeutics

Di cosa scriviamo

BiotecnologiaCardiologiaMedicina - VarieSaluteScienza

5 comunicati stampa

Guarda tutti i comunicati
20/05/2026
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Cardiologia
Medicina alternativa
Salute
Industria
HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Clinical Trial of HTX-001, an Investigational Precision Cellular Reprogramming Therapy for Cardiac Fibrosis
Fonte
HAYA Therapeutics
Emittente
Business Wire
1.00
0
03/06/2025
HAYA Therapeutics Moves San Diego Operations to Lilly Gateway Labs® to Accelerate Development of RNA-Guided Therapeutics Platform
Fonte
HAYA Therapeutics
Emittente
Business Wire
1.00
0
13/03/2025
HAYA Therapeutics Appoints Former Exscientia Executive Dr. Richard Law as Chief Business Officer
Fonte
HAYA Therapeutics
Emittente
Business Wire
1.00
0
11/09/2024
Multimedialità
Mercato del lavoro
Cardiologia
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Scienza
Medicina - Varie
HAYA Therapeutics Appoints Cardiology and Genetics Medicines Expert Jordan Shin, M.D., Ph.D. as Chief Medical Officer
Fonte
HAYA Therapeutics
Emittente
Business Wire
1.00
0
01/07/2024
HAYA Therapeutics Co-Founders Win Inaugural Andreas & Thomas Struengmann Award
Fonte
HAYA Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0